Coherus BioSciences Inc (CHRS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Coherus BioSciences Inc (CHRS) has a cash flow conversion efficiency ratio of -1.972x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-119.98 Million) by net assets ($60.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Coherus BioSciences Inc market cap and net worth for the company's overall valuation and market capitalisation.
Coherus BioSciences Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Coherus BioSciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Coherus BioSciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Coherus BioSciences Inc ranked by their cash flow conversion efficiency. Explore Coherus BioSciences Inc (CHRS) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Exacompta Clairefontaine
PA:ALEXA
|
0.200x |
|
Urbana Corporation
TO:URB-A
|
-0.006x |
|
TIL Limited
NSE:TIL
|
-0.256x |
|
QuantaSing Group Limited American Depositary Shares
NASDAQ:QSG
|
0.061x |
|
Kapston Services Limited
NSE:KAPSTON
|
0.016x |
|
Crexendo Inc
NASDAQ:CXDO
|
0.035x |
|
Global Green Chemicals Public Company Limited
BK:GGC
|
0.057x |
|
Krsnaa Diagnostics Limited
NSE:KRSNAA
|
0.056x |
Annual Cash Flow Conversion Efficiency for Coherus BioSciences Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Coherus BioSciences Inc from 2012 to 2025. View Coherus BioSciences Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $61.01 Million | $-138.51 Million | -2.270x | -1565.96% |
| 2024-12-31 | $-131.99 Million | $-20.44 Million | 0.155x | -82.87% |
| 2023-12-31 | $-193.43 Million | $-174.88 Million | 0.904x | -48.47% |
| 2022-12-31 | $-137.42 Million | $-241.12 Million | 1.755x | +558.10% |
| 2021-12-31 | $97.73 Million | $-37.43 Million | -0.383x | -169.82% |
| 2020-12-31 | $280.97 Million | $154.15 Million | 0.549x | +103.57% |
| 2019-12-31 | $105.21 Million | $28.36 Million | 0.269x | -93.47% |
| 2018-12-31 | $-38.59 Million | $-159.27 Million | 4.127x | +162.92% |
| 2017-12-31 | $30.54 Million | $-200.29 Million | -6.559x | +49.73% |
| 2016-12-31 | $19.35 Million | $-252.54 Million | -13.049x | -183.72% |
| 2015-12-31 | $-6.93 Million | $-107.99 Million | 15.585x | +4448.32% |
| 2014-12-31 | $66.76 Million | $-23.93 Million | -0.358x | +1.51% |
| 2013-12-31 | $-42.38 Million | $15.42 Million | -0.364x | +81.67% |
| 2012-12-31 | $9.19 Million | $-18.25 Million | -1.986x | -- |
About Coherus BioSciences Inc
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin… Read more